186 related articles for article (PubMed ID: 3049952)
1. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Quesada JR; Rios A; Swanson D; Trown P; Gutterman JU
J Clin Oncol; 1985 Nov; 3(11):1522-8. PubMed ID: 4056843
[TBL] [Abstract][Full Text] [Related]
4. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.
Itri LM; Campion M; Dennin RA; Palleroni AV; Gutterman JU; Groopman JE; Trown PW
Cancer; 1987 Feb; 59(3 Suppl):668-74. PubMed ID: 10822468
[TBL] [Abstract][Full Text] [Related]
5. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
Pazdur R; Ajani JA; Patt YZ; Winn R; Jackson D; Shepard B; DuBrow R; Campos L; Quaraishi M; Faintuch J
J Clin Oncol; 1990 Dec; 8(12):2027-31. PubMed ID: 2230894
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
11. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
13. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
Fosså SD
Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
Fosså SD; Lehne G; Gunderson R; Hjelmaas U; Holdener EE
Int J Cancer; 1992 Apr; 50(6):868-70. PubMed ID: 1372881
[TBL] [Abstract][Full Text] [Related]
17. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
18. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
20. Long-term interferon treatment in metastatic renal cell carcinoma.
Levens W; Rübben H; Ingenhag W
Eur Urol; 1989; 16(5):378-81. PubMed ID: 2776808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
